• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Parylene Coatings for Medical Device Technologies

    The Big Shift: Nearshoring Trends in Medtech Manufacturing

    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—Aug. 13

    'Graft-on-a-Chip' Built to Improve Vascular Graft Success

    Abbott Invests €440 in New Irish Facility

    FDA Approves Guardant Health's NGS-Based Companion Diagnostic

    Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Parylene Coatings for Medical Device Technologies

    The Big Shift: Nearshoring Trends in Medtech Manufacturing

    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Cooling and Melting the Pain Away

    What Are the Fundamentals of Go-To-Market Strategy in Medical Devices?

    Minding the Gap: How Harmonizing Quality Systems Pays Off

    Building Strong Partnerships Between Medtech and Surgeon-Learning Platforms

    Four Key Considerations for OEMs Transferring a Product Program
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    JBC Technologies

    Xact Wire EDM Corp.

    Trademark Plastics Inc.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Medical Computing: COM Express Processes Real-Time Data at the Edge

    The Importance of Building Successful Supplier Relationships

    The Benefits of Outsourcing Innovation in Medtech Manufacturing

    Patching Healthcare Cybersecurity Risks in the Internet of Medical Things

    Leveraging Open Healthcare Data Standards to Improve Medical Device Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    JBC Technologies

    Xact Wire EDM Corp.

    Trademark Plastics Inc.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    The Buck Starts Here

    ...

    The Buck Starts Here
    Related CONTENT
    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    • Accu-Tube Appoints Matthew Haddle as CEO
    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    • CE Mark Granted to Predictive Software for Kidney Allograft Survival
    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Steve Maylish, Chief Commercial Officer, Fusion Biotec, and Ben Bobo, CEO, NeuroTemp LLC06.06.17
    Commercialization is the confluence of all prior activities, a time of high investment and high anxiety. Here the rubber meets the road—yet for a new device, visibility on that road is often quite poor. A regulatory agency approved your device for sale, but how do you get traction? If you build it (to meet your pricing target), will they come?

    Although established medical device companies have a more predictable path, product commercialization brings risk and uncertainty. Go-to market strategies often resemble a slog in the fog rather than a well-executed plan. Companies pull familiar levers of market research, product design, and clinical trials. Marketing applies the leverage of key opinion leaders (KOLs), Centers of Excellence (COE), peer-reviewed journals, clinical partners, and voice of the customer to maximize the offering’s impact and drive commercial certainty up and down corporate structure. However, according to a survey of 2,240 executives from McKinsey Global, only 39 percent feel confident in their company’s ability to commercialize a medical device. Commercialization is truly an art form; no one product, market, or customer acts predictably to the traditional commercial levers.

    In reality, no one can predict whether a product will be successful and become standard of care. The unreasonable pressure executives endure to deliver a revenue- producing product under budget and under schedule adds to this dynamic. Most of the mistakes that cost investors millions, significantly dilute key shareholders, hurt stock prices, and run startups out of business are made here. Commercialization is the culmination of a dream to deliver a disruptive and breakthrough medical device, but innovators, inventors, and engineers can fail to adequately filter ideas and designs through the most important element—the customer. Teams can fall victim to “drinking their own Kool-Aid” or to the pressure of executing the plan and miss the basics of product development.

    Presuming market research identified a unique clinical problem to solve with large market potential and a disruptive design approach, the Customer Requirements Document (CRD) is the greatest determinant of a successful commercial launch. The CRD provides specifications of what the customer wants the product to do in a clinical environment, based on their understanding of the technology. The Product Requirements Document (PRD) provides all the engineering requirements for what the product should do.

    When the CRD and PRD are misaligned, the product may not achieve commercial liftoff. The initial CRD and PRD provide a line in the sand to start development. However, these are living documents that evolve during the development process—expect them to evolve as KOLs interact with the device and provide feedback. Too often, this feedback occurs late in the process. This should change because of the new U.S. Food and Drug Administration (FDA) usability requirements. (Some of these new requirements are outlined in my article entitled “The Human Factor” in the May issue of MPO.)

    These evolving product features and iterations will, however, be in direct conflict with budgets, timelines, and expectations of executives and investors. The process can be cut short as undue pressure is applied; the product has a higher chance of failing in the clinical setting in these cases. An experienced R&D leader should provide a buffer between the development and executive teams. Investors will espouse—and project leaders will confirm—that projects usually take twice as long and cost twice as much as initially expected. This reality is often based on tasks unknown during budgeting and the discovery process of development. Project plans show milestones and a waterfall process, but feedback and iteration underlie the entire process.

    No one is prepared when a product misses its clinical mark during clinical studies. The design can be prototyped and tested, but the team can still fail to appreciate the impact of environmental factors on their design, customer requirements, or the technology’s failure to deliver on its promise. Since iterating the design at the end of development is expensive and time consuming, many assume clinical problems will be solved with enough training and education.

    One company developed a novel non-invasive monitoring technology and spent six years and over $12 million on a design unsuitable for the ICU environment and an accuracy that would never be clinically acceptable. Had the company invested in early prototypes with leading neurosurgeons and nurses, their understanding of the customer requirements and target the design needed to hit would have been dramatically different. This is the innovator’s dilemma: not listening to the customer/user throughout the process.

    Throughout the product development process, “commercialization” activities happen in parallel. These can be as varied as human factors, design for manufacturing, or clinical testing. The main factor in determining the market for a new device is identifying an unmet clinical need for a procedure, or a step in a procedure. Some companies are formed by an idea looking for an application. It’s far better to start with an unmet clinical need.

    For example, one company pioneered beating heart surgery. The unmet clinical need in this case was preventing patients from undergoing open-heart surgery on a heart/lung machine and avoiding the deleterious effects of cardiopulmonary bypass. The result: the company took 20 percent of the coronary artery bypass market and was sold for $313 million.

    There is a huge difference between how a large established medical device (LEMD) company and a start-up launches a product. A LEMD has established sales channels (40- to 200-person sales forces), KOLs, and an established brand name for product quality. They also have established national accounts that can be leveraged to promote the product into leading centers. Even with these built-in advantages, LEMDs still take a conservative approach to product introductions to customers.

    Typically, they identify thought leader sales representatives (TLRs) in their organizations that influence the sales teams. They target COEs in territories of TLRs to initiate the product launch with the purpose of developing sales messaging and “recipes for success.” Twenty to twenty five centers may be targeted in this phase to flesh out the price, promotion, and positioning of the product in the customer’s mind. Usually four to six months afterward, they will do a market release with the full sales organization. The TLRs will be active in this phase to lend credibility and gravitas to the product launch.

    Startups have a different challenge. They lack a brand name, national accounts, a distribution channel of sales pros with KOLs, and sometimes funding. A startup has two distinct options to develop its sales channel. First is a direct sales force, which brings the advantage of controlling the sales strategy. Going direct is expensive and adds dramatically to the burn rate. This can materially impact the company’s operations if the product is not ready for launch. Most startups do not have the luxury to add an eight- to 10-person sales team. Experienced, successful sales reps are highly paid, but inexperience doesn’t get you through the door.

    Identifying and training independent distributor sales reps to sell and promote the product is another option. However, the decision to use distributor reps should not be made for purely financial reasons. If the distributor reps also promote products with shorter sales cycles and minimal levels of approval, the startup can lose control of their strategy. It’s easy to feel abandoned; distributors typically have multiple products in their bag.

    Startup medical device companies passionately usher in new technology while facing the challenges of funding, development, and regulatory agencies in order to change the market and bring life-saving technology to patients in need. It may have taken at least 24 grueling months to get to product launch, but the distributor doesn’t have skin in the game and is often fixated on products driving short sales cycles and quick payment.

    When considering a distributor strategy, consider the sales cycle of your product and ensure you identify distributors comfortable working a six- to nine-month process. If your product isn’t ready for commercial release, distributors will focus on products creating a path to commissions.

    At this point, hindsight is 20/20. The distributors have given the ultimate gift of feedback—because in commercial terms, one only gets a couple of bites at the apple to make an impression in the marketplace. It’s hard to make a second impression (and recover with subsequent launches) if the product rollout looks half-baked, with a technology faltering out of the gate. Unfortunately, modifying a design can also mean resubmitting to the FDA.

    As sales falter, inventory grows. This ties up cash. Investing too much in inventory or factory automation before product launch increases company risk, even if it reduces unit cost. Additionally, as sales increase, manufacturing is strained. This problem is solvable—scaling manufacturing should be carefully timed with the product rollout. Manual manufacturing processes can provide flexibility during commercialization, but there should also be a quick and clear path to ramp when needed.

    Once the essentials are covered, the company must consider the estimated usage per institution. This bottom-up approach provides a more accurate sales forecast. When converting an institution, understand the competition and any existing group purchasing organization (GPO) contracts needing circumvention.

    GPOs and integrated delivery networks (IDN, a system of providers) control much of the decision-making for capital equipment. A healthy GPO and IDN strategy must exist. According to Definitive Healthcare, 97 percent of hospitals are affiliated with GPOs. The Healthcare Supply Chain Association also suggests GPOs manage about 72 percent of the purchases in hospitals.

    U.S. health data based on the U.S. Centers for Medicare and Medicaid Services found from 2013 to 2022, GPOs are expected to generate savings of up to $864 billion for the U.S. health system and their members. GPOs like Premier and Vizient together supply close to 1 million hospital beds. Vizient alone represents almost $100 billion in annual purchasing volume, but don’t assume members are loyal to a corporate contract. More than ever, cost containment and patient outcome data is crucial to survival.

    Almost 80 percent of institutional C-Suite executives have resource utilization programs in place to control the use of supplies and services. Value analysis committees delay the introduction of new products because each potential entrant must be vetted. Companies need to articulate the product’s measurable value, then prove it. If not, new devices will be commoditized (resulting in a lower price) or never purchased. They also have to be creative—for example, through an equipment lease, pay-per-use agreement, or risk-based contracts. Companies also need to know which contracting approaches provide institutional customers the most value.

    Obsess over customer feedback during the development phase and embrace negative input. If treated and handled correctly, each negative pearl is worth millions in valuation potential. Throughout the development process, keep an open mind, engage the customer often, and be willing to make changes. Solving a unique clinical problem in close coordination with the customer often results in a disruptive design approach. Hiring the right sales team to sell the right product is the only way to clear some fog on the road ahead. Once this is done, don’t underestimate the value of a comprehensive sales strategy. Commercialization will always be a time of high anxiety, but there’s no quicker road to success than taking the time to do it right. 


    Steve Maylish has been part of the medical device community for more than 30 years. He is currently chief commercial officer for Fusion Biotec, an Irvine, Calif.-based contract engineering firm that brings together art, science, and engineering to create medical devices. Early in his career, Maylish held positions at Fortune 100 corporations such as Johnson & Johnson, Shiley, Sorin Group, Baxter Healthcare, and Edwards Lifesciences.

    Ben Bobo is a senior medical device/healthcare technology executive with experience as a CEO, CCO, and COO. His background includes extensive sales and marketing successes in VC-funded start-up, early commercial stage, and multibillion-dollar corporate environments. Bobo has held positions with Edwards Lifesciences, Cardio Thoracic Systems, Guidant, and CardioVention. He has a BS in economics and an MBA from the University of Phoenix.
    Related Searches
    • fda
    • change
    • non-invasive
    • product development
    Related Knowledge Center
    • R&D & Design
    Suggested For You
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    Accu-Tube Appoints Matthew Haddle as CEO Accu-Tube Appoints Matthew Haddle as CEO
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    CE Mark Granted to Predictive Software for Kidney Allograft Survival CE Mark Granted to Predictive Software for Kidney Allograft Survival
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Precision Coating Merges with N2 Biomedical Precision Coating Merges with N2 Biomedical
    Presidio Medical Names Michael Onuscheck as CEO Presidio Medical Names Michael Onuscheck as CEO
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    RapidPulse Closes $15 Million Series A Financing RapidPulse Closes $15 Million Series A Financing
    Midwest Products & Engineering Acquires MindFlow Design Midwest Products & Engineering Acquires MindFlow Design
    Vicarious Surgical Opens New Corporate Headquarters in Massachusetts Vicarious Surgical Opens New Corporate Headquarters in Massachusetts
    Luis J. Malavé Joins Integrity Applications Board Luis J. Malavé Joins Integrity Applications Board

    Related Breaking News

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21

    • Tubing & Extrusion
      Accu-Tube Appoints Matthew Haddle as CEO

      Accu-Tube Appoints Matthew Haddle as CEO

      Haddle has a track record of leading organizations through strategic expansions across the medical device, aerospace, and industrial sectors.
      Accu-Tube 09.22.21

    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21


    • CE Mark Granted to Predictive Software for Kidney Allograft Survival

      CE Mark Granted to Predictive Software for Kidney Allograft Survival

      Algorithm gives the probability the graft will still be functional at three, five, and seven years after evaluation by a healthcare professional.
      Cibiltech 09.21.21

    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Sleeve based on a medical technique called Direct Wire Pacing, which was invented by the company’s founder.
      Electroducer 09.21.21

    Loading, Please Wait..

    Trending
    • BD Recalls Intraosseous Products Over Multiple Issues
    • Abbott Invests €440 In New Irish Facility
    • RSNA 2021: Canon Medical Unveils Vantage Fortian 1.5T MRI
    • Chronic, Infectious Disease Prevalence To Benefit Vital Signs Monitoring Market
    • 7 Considerations For Designing Medical Device Mechanisms
    Breaking News
    • MPO's Most-Read Stories This Week—Aug. 13
    • 'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    • Abbott Invests €440 in New Irish Facility
    • FDA Approves Guardant Health's NGS-Based Companion Diagnostic
    • Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Parylene Coatings for Medical Device Technologies
    • Nearshoring Trends in Medtech Manufacturing
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    What are you Reading this Week?
    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Aug. 13
    'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    Abbott Invests €440 in New Irish Facility
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AskBio Appoints Clinical Ops Executives
    SpectrumX Partners With UK Contract Manufacturer
    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arkay Chairman Emeritus Howard Kaneff Has Died
    Nutricosmetics Market to Hit $13.7 Billion by 2030
    Estée Lauder Pledges 100% Electric Fleet of Vehicles by 2030
    Happi

    Latest Breaking News From Happi

    Consumers are Clamoring for Vintage Glam: Spate
    Kayali’s Lovefest Fragrance, Newell’s New Candle and HydraFacial’s Record Financial Results
    Self Care Trumps Home Care Post-Covid
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Printing Ink Primer, Zeller+Gmelin Lead This Week’s News Stories
    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Esko, Constantia Flexibles announce acquisitions and more
    Hybrid Software joins The Flexo Xperience Center
    Flexo Wash LLC and Mike Potter celebrate 20 years
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Essity Switches to Recyclable Packs for Feminine Pads, FTC Sues PPE Maker on False Origin Claims & More
    Focke & Co. to Host Destination: Your Hygiene Hub on August 31
    Exports Dominate Chinese Trade of Tissues, Hygiene Products and Wipes
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Aug. 13
    Dental 3D Printing Market is Expanding 20% Annually
    Study Results Released for Abbott's Concussion Blood Test
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: ALTANA, Universal Display and Emerson Top This Week’s Stories
    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login